
Waters (WAT) Stock Forecast & Price Target
Waters (WAT) Analyst Ratings
Bulls say
Waters is a company with strong potential for growth, especially in the diagnostics and biosciences sectors, following its merger with Becton Dickinson in early 2026. The company also has a strong management team and a solid reputation in the pharmaceutical market. However, the high levels of debt and limited data on pricing for global shipping present potential risks for the company's financials and the broader Medical and Life Science Tools sector. Investors should monitor the company's capital allocation strategies and closely follow any price increases for their products.
Bears say
Waters is a company that has expanded its market through a recent merger with Becton Dickinson's life science and diagnostics business, but with its increased concentration in diagnostics and discovery-related life science tools, the negative outlook is justified. The integration of BD assets adds operational complexity at a potential industry inflection point, and the risk of integration hiccups and growth disappointment could compress the company's valuation. Additionally, concerns over its sustainability efforts and potential pricing pressure due to increased scrutiny and regulatory expectations could further impact the company's future growth potential.
This aggregate rating is based on analysts' research of Waters and is not a guaranteed prediction by Public.com or investment advice.
Waters (WAT) Analyst Forecast & Price Prediction
Start investing in Waters (WAT)
Order type
Buy in
Order amount
Est. shares
0 shares